Evaluation of DB818 and DB1055 on human AML cell lines and blasts isolated from AML patients evidences interesting differentiation and anti-leukemic activities, highlighting the targeting of the HOXA9 cognate sequence, and an original and promising strategy to inhibit HOXA9 leukemogenic function (submitted manuscript, personal communication). This evidence concerns the gene HOXA9 and acute myeloid leukemia.